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Background: The aim of this study was to investigate the relationship between the polymorphisms of the
methylenetetrahytrofolate reductase (MTHFR) gene and susceptibility to childhood acute lymphoblastic leukemia (ALL).
Methods: A case–control study was conducted among 98 children with ALL and 93 age- and sex- matched
non-ALL controls. Genotyping of MTHFR C677T and A1298C polymorphisms was performed by polymerase chain
reaction-restriction fragment length polymorphism (PCR-RFLP). The odds ratios (ORs) of MTHFR genotypes were used
to assess the associations of these polymorphisms with childhood ALL susceptibility.
Results: No significant differences were observed for frequencies of the 677CC, 677CT and 677TT genotypes between
patients and controls. Frequencies of the 1298AA, 1298 AC and 1298CC genotypes between the two groups were
significantly different. The risk of ALL with the 1298C allele carriers (AC + CC) was elevated by 1.1 times compared with
the AA genotype [OR = 2.100; 95% CI (1.149; 3.837); P = 0.015].
Conclusions: The MTHFR A1298C polymorphism is associated with susceptibility to childhood ALL in the
Chinese population.
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Acute lymphoblastic leukemia (ALL) is a malignant dis-
order of lymphoid progenitor cells with a peak prevalence
at the ages 2–5 years old [1] and accounts for one third of
all childhood malignancies [2,3]. Although the rapid pro-
gress in the clinical diagnosis and effective treatment of
childhood ALL has led to a cure rate of more than 80% in
children [4], the precise pathogenesis of ALL is not clearly
known. With the development of genetic pharmacology,
people have gradually realized that individual differences in
disease are mainly due to genetic polymorphisms, espe-
cially single nucleotide polymorphisms (SNPs) [5]. SNPs, a* Correspondence: minling-chen@163.com
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reproduction in any medium, provided the ortype of polymorphism involving variation of a single base
pair, may directly affect the structure or expression of the
protein. Therefore, the characterization and detection of
the SNP distribution differences in different populations
will help to identify human susceptibility genes related to
some diseases.
Polymorphisms of the methylenetetrahydrofolate re-
ductase (MTHFR) gene were shown to be associated
with leukemogenesis [6]. MTHFR is a folate metabolic
enzyme, catalyzing the reduction of 5,10-methylenetetra-
hydrofolate to 5-methyltetrahydrofolate [7,8]. Two com-
mon SNPs of the MTHFR gene, C677T and A1298C, have
been identified. MTHFR C677T converts alanine into val-
ine at codon 222, and A1298C converts glutamic acid into
alanine at codon 429. Changes in these two loci can lead to
decrease of enzyme activity and plasma folate level, as well
as homocysteine level elevation [9]. Associations of thehis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tate cancer, colorectal cancer, renal carcinoma and bladder
cancer, have also been proposed [8,10]. Recently, the
relativity between MTHFR polymorphisms and suscep-
tibility to childhood ALL has come under intense scru-
tiny [2,6,11-16]. Because the MTHFR gene distribution
varies among different populations [3,6], although rela-
tionships of MTHFR polymorphisms and leukemia in
different populations have been reported [2,6,11-19],
whether C677T and A1298C gene polymorphisms are in-
volved in the susceptibility to childhood leukemia remains
largely controversial.
In the present study, we used the polymerase chain
reaction-restriction fragment length polymorphism (PCR-
RFLP) technique to investigate whether MTHFR poly-
morphisms and their allele frequency may be correlated




From October 2007 to April 2011, a total of 98 children
(54 boys, 44 girls) with ALL were diagnosed by bone
marrow cytology in Nanjing Children’s Hospital, Nanjing,
China. Patient ages ranged from 0.9 to 11 years old (mean,
5.1 years old). Meanwhile, a total of 93 controls (1.2-
13 years old; mean, 5.7 years old) hospitalized during the
same period were recruited from clinical departments
other than hematology or oncology of Nanjing Children’s
Hospital. The controls had no blood disease or family
history of ALL assessed by medical history and clinical
examination. There was no significant difference between
the two groups in gender and age distribution (P > 0.05).
All individuals and/or their parents provided informed
consent to participate in this study, and the protocol was
approved by the medical research ethics committee of
Nanjing Children’s Hospital.
Genotyping of MTHFR variants
MTHFR C677T and A1298C polymorphisms were de-
tected by PCR-RFLP assay as described by Atashrazm
et al. [3] with slight modification. A total of 2 ml venous
blood was extracted from each subject, and EDTA was
used for anticoagulation. The conventional phenol-
chloroform extraction method was used to extract the
genomic DNA. MTHFR gene exon 4 (containing C677T
polymorphism site) and exon 7 (including A1298C poly-
morphic site) were amplified by PCR. Primer sequences
and the annealing temperature of PCR are presented in
Table 1. For the details, the PCR thermal cycling condi-
tion included 35 cycles of 95°C for 5 min, 94°C for 30 s,
56°C or 55°C (for polymorphic sites at positions 677 and
1298, respectively) for 1 min, 72°C for 30 s and 72°C for
8 min. Primers were designed using Premier 5 softwareand synthesized by the Beijing Genomics Institute (Beijing,
China). The primer’s specificity was confirmed by BLAST
in Genbank.
Restriction endonuclease mapping analysis
MTHFR C677T: the PCR products were digested by
HinfI (TaKaRa, Dalian, China) after overnight incubation
at 37°C. The final products were subjected to electro-
phoresis on 2% agarose, and the genotypes were deter-
mined by examining the stained gel in 0.2% ethidium
bromide. A fragment of 387 bp indicated a CC wild
genotype; 3 fragments of 387, 235 and 152 bp were indica-
tors of a CT heterozygote; a TT homozygous mutant pro-
duced two fragments of 235 bp and 152 bp, respectively.
MTHFR A1298C: PCR products were digested with
MboII (TaKaRa, Dalian, China). The final products were
subjected to electrophoresis on 2% agarose, and the
genotypes were determined by examining the stained
gel in 0.2% ethidium bromide. The AA wild genotype
produced five fragments of 56, 31, 30, 28 and 18 bp,
respectively; the AC heterozygote produced six of frag-
ments 84, 56, 31, 30, 28 and 18 bp, respectively; the CC
homozygous mutant produced four fragments of 84, 31,
30 and 18 bp, respectively. GENESCAN™672 software
(Applied Biosystems, Foster City, CA, USA) was used for
collecting information from every band, and GeneMapper
software (Applied Biosystems, Foster City, CA, USA) was
used to analyze the data.
Statistical analysis
Data were input into Epidata3.0 to establish a database.
Statistical analysis was performed by SPSS16.0 (SPSS
Inc., Chicago, IL, USA). Hardy-Weinberg equilibrium
was assessed by the χ2 goodness of fit test. Genotype
and allele frequencies were expressed by percentile, and
the haplotype and linkage disequilibrium were estimated
by SHEsis software (Bio-X Life Science Research Center
of Shanghai Jiao Tong University, Shanghai, China). The
χ2 test was used to examine differences in MTHFR geno-
types and allele frequencies between cases and controls.
The odds ratio (OR) and 95% confidence interval (CI)
were used for correlation analysis of ALL morbidity, and




Genotype distributions for both markers among control
and ALL groups were found to be in HWE (Table 2).
MTHFR C677T genotype and allele frequency distribution
Genotype and allele frequency for MTHFR C677T is
shown in Table 3. Frequencies of 677CC, 677CT and
677TT were 28.6%, 44.9% and 26% in the ALL group
Table 1 Characteristics of PCR primers sequence, target fragment length and annealing temperature used for
genotyping MTHFR polymorphisms
Polymorphisms sites Primers sequence (5′→ 3′) Fragment length Annealing temperature
MTHFR C677T F AGTCCCTGTGGTCTCTTCATC 387 bp 56°C
R GGAGATCTGGGAAGAACTCAG
MTHFR A1298C F CTTTGGGGAGCTGAAGGACTACTAC 168 bp 55°C
R CACTTTGTGACCATTCCGGTTTG
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spectively. No significant differences in genotype distri-
butions of MTHFR C677T were found between the ALL
group and control group (χ2 = 3.109, P = 0.211). The 677 T
allele frequency distribution between the two groups
also showed no significant difference (49.0% vs. 42.5%,
χ2 = 1.627, P = 0.202).
MTHFR A1298C genotype and allele frequency distribution
Genotype and allele frequency for MTHFR A1298C is
shown in Table 4. Frequencies of 1298CC, 1298CT and
1298TT were 55.1%, 42.9% and 2.0% in the ALL group
and 72.0%, 26.9% and 1.1% in the control group, respect-
ively. The overall distributions of MTHFR A1298C geno-
type frequencies in the two groups were significantly
different (χ2 = 5.917, P = 0.05). MTHFR 1298C allele fre-
quency in the ALL group was significantly higher than
that in the control group (23.5% vs. 14.5%, χ2 = 4.949,
P = 0.026). Besides, from Table 4, we find that the OR of
genotype CC is too large (0.219-28.104), which might re-
sult from the very low number of CC cases (two cases).
Therefore, we combined the genotypes of AC and CC to
calculate the distribution. The C allele (AC +CC genotype)
frequency in the ALL group was significantly higher than
that in the control group (44.96% vs. 28.0%, χ2 = 5.898,
P = 0.015), and the C allele (AC +CC) carriers had a 1.1
times higher risk of ALL than the AA genotype carriers
(OR = 2.100, 95% CI: 1.149 − 3.837).
Discussion
In recent years, many articles have reported on the
MTHFR polymorphism and susceptibility to ALL, but they
are soundly inconclusive. In this study, by investigatingTable 2 Compositions of the MTHFR C677T genotype and MTHF
MTHFR C677T genotype
ALL group Control group
CC type 28 (28.6%) 29 (31.2%)
CT type 44 (44.9%) 49 (52.7%)
TT type 26 (26.5%) 15 (16.1%)
χ2 1.013 0.569
P-value 0.314 0.451the distribution of MTHFR C677T and A1298C genotypes
and their allele frequencies in ALL children and non-ALL
controls, we found that MTHFR A1298C was significantly
related to the susceptibility to childhood ALL.
In 1999, Skibola et al. [20] first reported that the
MTHFR C677T mutation could reduce the susceptibility
to adult ALL, and their results suggested that the risk of
ALL was reduced by 4.3 times for people carrying the
TT genotype. Subsequently, Franco et al. [21] had simi-
lar findings that the C677T mutation can reduce the risk
of childhood ALL. Later, multiple documents reported a
protective effect of the TT genotype on the pathogenesis
of ALL [3,6,11,12,]. However, the association is mostly
not statistically significant [3,13], and some studies even
suggested that the C677T mutation is an ALL risk factor
[22]. A meta-analysis including 13 studies with a total of
4,894 individuals indicated that the C677T mutation was
not associated with childhood ALL [23]. In this study, we
also report a statistically non-significant difference of geno-
type frequencies among cases and controls, indicating that
the MTHFR C677T gene polymorphism has no relation to
the risk of childhood ALL. This result is in accordance with
the results of Atashrazm et al. [3] and Oliveira et al. [13].
The MTHFR A1298C polymorphism was associated
with an elevated risk of childhood ALL [6]. Alcasabas
et al. [7] found that the ALL risk of MTHFR 1298C car-
riers (AC + CC type) was 1.57 times higher than that of
the AA genotype carriers. Kim et al. [24,25] had similar
findings. Other studies in Germany [17], the UK [2],
north Indian [18] and Kurdish [19] showed no associa-
tions between the MTHFR A1298C polymorphism and
risk of ALL. In our study, the risk of ALL in MTHFR
1298 AC genotype carriers was 2.084-fold that of theR A1298C genotype in the Hardy-Weinberg equilibrium test
MTHFR A1298C genotype
ALL group Control group
AA type 54 (55.1%) 67 (72.0%)
AC type 42 (42.9%) 25 (26.9%)
CC type 2 (2.0%) 1 (1.1%)
χ2 3.652 0.643
P-value 0.06 0.423
Table 3 Frequencies of MTHFR C677T polymorphisms in childhood ALL patients and controls
MTHFR C677T Patient no. (%) Control no. (%) χ2 P OR (95%CI)
Genotype
CC 28 (28.6) 29 (31.2) - 1.00#
CT 44 (44.9) 49 (52.7) 0.046 0.829 0.930 (0.481 − 1.799)
TT 26 (26.5) 15 (16.1) 1.969 0.161 1.795 (0.790 − 4.079)
CT + TT 70 (71.4) 64 (68.8) 0.155 0.693 1.133 (0.609 − 2.106)
Allele
C 100 (51.0) 107 (57.5) - 1.00#
T 96 (49.0) 79 (42.5) 1.627 0.202 1.300 (0.868 − 1.947)
#As reference group; OR, crude odds ratio; —, not applicable; CI, confidence interval. CC, CT and TT overall distribution test, χ2test = 3.109, P = 0.211.
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3.841, P = 0.018), and the OR of the MTHFR A1298C
genotype for AC + CC between patients and controls was
2.100 (95% CI, 1.149 − 3.837; P = 0.015). This indicates
that A1298C is a risk factor for childhood ALL in the
Chinese population, which is in accordance with the
results of previous studies [6,7,24,26].
These data indicate that the MTHFR A1298C but not
the C677T polymorphism is a potential biomarker for
childhood ALL risk in the Chinese population, which is
inconsistent with the results of Yan et al. [25] and Tong
et al. [27]. We speculated that the inconsistent results in
the relationship between MTHFR gene polymorphisms
and childhood ALL in different studies might result from
the following reasons: first, MTHFR gene distribution var-
ied among different populations [6]; second, MTHFR poly-
morphisms may be affected by the level of intracellular
folate, which is related to eating habits and nutritional in-
take; third, single SNPs provide insufficient information
for comprehensive analysis of the MTHFR polymorphism;
besides, other genes may regulate the susceptibility to
childhood ALL, such as RFC1 80G > A and NNMT
IVS −151C >T variants [12]. Eventually, linkage of haplo-
types in the two loci would help to identify genetic markers
associated with drug response differences.Table 4 Frequencies of MTHFR A1298C polymorphisms in chil
MTHFR A1298C Patient no. (%) Control no. (%)
Genotype
AA 54 (55.1) 67 (72.0)
AC 42 (42.9) 25 (26.9)
CC 2 (2.0) 1 (1.1)
AC + CC 44 (44.9) 26 (28.0)
Allele
A 150(76.5) 159 (85.5)
C 46(23.5) 27 (14.5)
*Corrected chi-square test; #as reference group; OR, crude odds ratio; —, not applic
χ2test = 5.917, P = 0.05.The level of MTHFR 1298CC homozygous mutation is
relatively low. In the present study, there were only two
cases with CC genotypes among 98 patients. The previous
studies found that the 1298CC homozygous mutation rate
was only about 10% [3,12,18,20]. Thus, we speculated that
the lower number of CC cases in this study was caused by
the low total number of cases in this study (98 patients
and 93 controls), which may induce a high occasionality.
Therefore, we combined the genotypes of AC and CC to
calculate the distribution of MTHFR A1298C to improve
the reliability of our findings.
It is important to note that the small sample size is a
major limitation in our study because only 98 cases and
93 controls were included. However, our study is still
significant for providing valid data on MTHFR C677T
and A1298C genotypes for further study of MTHFR
polymorphisms and childhood ALL in the Chinese
population. In addition, more case–control studies with
larger sample sizes and more genotypes of different ethnic
pediatric populations are necessary.
Conclusion
In conclusion, we investigated the relationship between
the polymorphism of MTHFR C677T and A1298C muta-
tion and the susceptibility to childhood ALL by PCR-RFLPdhood ALL patients and controls
χ2* P OR (95%CI)
- 1.00#
5.628 0.018 2.084 (1.131 − 3.841)
0.574 0.449 2.481 (0.219 − 28.104)
5.898 0.015 2.100 (1.149 − 3.837)
- 1.00#
4.949 0.026 1.806 (1.068 − 3.053)
able; CI, confidence interval. AA, AC and CC overall distribution test,
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sults indicated that the MTHFR A1298C polymorphism,
not C677T, is associated with susceptibility to childhood
ALL in the Chinese population. However, in the future, it
will be necessary to expand the sample size and consider
additional factors for exploring the relationship between
the MTHFR polymorphism and the incidence of ALL to
provide more accurate information for clinical research.
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